This is illustrated by the clinical trial providing initial evidence for the utility of Crizotinib in EML4-ALK positive lung cancer comprising 105 study-centers in 27 countries but with only 347 patients[8] or another study that found only 44 ALK-, 14 RET- and 13 ROS1-fusions in 1,529 lung adenocarcinomas[9]. Here, ALK is linked to lung adenocarcinoma.